Baxdela

Chemical Namedelafloxacin
Dosage FormTablet (oral; 450 mg), injection (intravenous; 300 mg)
Drug ClassAntibacterials
SystemSkin, Respiratory
CompanyMelinta
Approval Year2017

Indication

  • For the treatment of adults with the following infections caused by designated susceptible bacteria: Acute Bacterial Skin and Skin Structure Infections
  • For the treatment of adults with the following infections caused by designated susceptible bacteria: acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Baxdela (delafloxacin) Prescribing Information2019Melinta Therapeutics, Inc., Lincolnshire, IL